Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

EGFR tyrosine kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Btk (4) EGFR (113) Apoptosis (27) Autophagy (33) Bcr-Abl (1) BMX Kinase (1) c-Met/HGFR (2) CaMK (2) Casein Kinase (1) CDK (1) COX (1) DNA-PK (1) Drug Metabolite (3) Drug-Linker Conjugates for ADC (3) Endogenous Metabolite (3) Enterovirus (1) Ephrin Receptor (1) Epigenetic Reader Domain (1) ERK (1) Ferroptosis (9) FGFR (5) GLUT (1) GPR35 (1) HCV (2) Histone Acetyltransferase (1) IGF-1R (2) Influenza Virus (2) IRAK (2) Isotope-Labeled Compounds (8) JAK (2) MMP (1) mTOR (1) p38 MAPK (1) PDGFR (5) Phosphatase (1) Phosphodiesterase (PDE) (2) PI3K (1) PKA (1) PKC (1) PROTACs (1) Ras (1) RET (1) ROR (1) Src (6) STAT (2) TGF-β Receptor (1) Topoisomerase (1) Trk Receptor (2) Tyrosinase (1) VEGFR (15)
By Research Areas:	Cancer (136) Cardiovascular Disease (3) Infection (4) Inflammation/Immunology (3) Metabolic Disease (3) Neurological Disease (1)
Click Chemistry:	Azide (1) Alkynes (6)

141

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: EGFR Btk Syk DYRK Pyk2 BRK FAK FLT3 Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P2503

EGFR Protein Tyrosine Kinase Substrate	EGFR	Cancer
EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate.

HY-117155

PKI-166 1 Publications Verification	EGFR	Cancer
PKI-166 is a potent, selective and orally bioavailable **EGFR tyrosine kinase inhibitor, with an IC₅₀** of 0.7 nM .

HY-107459

(E/Z)-AG490 (E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42	EGFR STAT JAK	Cancer
(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a **tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3**.

HY-12972

Mavelertinib PF-06747775	EGFR	Cancer
Mavelertinib is a selective, orally available and irreversible EGFR tyrosine kinase inhibitor (EGFR TKI), with IC₅₀s of 5, 4, 12 and 3 nM for Del, L858R, and double mutants T790M/L858R and T790M/Del, respectively. Mavelertinib can be used for the research of non-small-cell lung cancer (NSCLC) .

HY-110328

PKI-166 hydrochloride	EGFR	Cancer
PKI-166 hydrochloride is a potent, selective and orally active **EGFR tyrosine kinase inhibitor, with an IC₅₀** of 0.7 nM .

HY-144444

NSC381467	EGFR	Cancer
NSC381467 is a potent and orally active inhibitor of EGFR tyrosine kinase (EGFR-TK). NSC381467 has strong antiproliferative activities. NSC381467 has the potential for the research of cancer diseases .

HY-144445

NSC114126	EGFR	Cancer
NSC114126 is a potent and orally active inhibitor of EGFR tyrosine kinase (EGFR-TK). NSC114126 has strong antiproliferative activities. NSC114126 has the potential for the research of cancer diseases .

HY-120036

Tyrphostin AG1112	Casein Kinase Tyrosinase	Cancer
Tyrphostin AG1112 is a potent inhibitors of CK II. Tyrphostin AG1112 inhibits p210 ^bcr-abl tyrosine kinase, with IC₅₀ values of 2, 15, 20 μM in p210 ^bcr-abl, EGFR and PDGFR cells, respectively .

HY-50896S

Erlotinib-d6 CP-358774-d₆; NSC 718781-d₆; OSI-774-d₆	EGFR	Cancer
Erlotinib-d₆ (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR[1]. Erlotinib-d6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-21291

SU-4313	PDGFR EGFR IGF-1R	Cancer
SU-4313 is a potent *protein tyrosine* kinases (PTKs) modulator with IC₅₀*s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase* and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation .

HY-50895

Gefitinib Maximum Cited Publications 129 Publications Verification ZD1839	EGFR Autophagy Apoptosis	Cancer
Gefitinib (ZD1839) is a potent, selective and orally active **EGFR tyrosine kinase inhibitor with an IC₅₀ of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC₅₀ of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis**, which can be used for cancer related research, such as Lung cancer and breast cancer .

HY-50895B

Gefitinib dihydrochloride ZD 1839 dihydrochloride	EGFR Autophagy Apoptosis	Cancer
Gefitinib (ZD 1839) dihydrochloride is a potent, selective and orally active **EGFR tyrosine kinase inhibitor with an IC₅₀ of 33 nM. Gefitinib dihydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC₅₀ of 54 nM) and blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib dihydrochloride also induces autophagy and cell apoptosis**, which can be used for cancer related research, such as Lung cancer and breast cancer .

HY-149051

BGB-8035	Btk	Inflammation/Immunology Cancer
BGB-8035 is an orally active, highly selective *bruton's tyrosine* kinase (BTK) inhibitor with IC₅₀*s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR*, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research .

HY-112823A

Almonertinib mesylate 3 Publications Verification HS-10296 mesylate	EGFR	Cancer
Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation *EGFR* tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer .

HY-112412

PDGFR Tyrosine Kinase Inhibitor III PDGF Receptor tyrosine kinase Inhibitor III	PDGFR	Neurological Disease
PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis .

HY-50896S1

Erlotinib-13C6 CP-358774-¹³C₆; NSC 718781-¹³C₆; OSI-774-¹³C₆	Isotope-Labeled Compounds EGFR Autophagy	Cancer
Erlotinib- ¹³C₆ is a ¹³C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1].

HY-164718

Sevabertinib	EGFR	Cancer
Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity .

HY-108484

PP 3	EGFR	Cancer
PP 3 (Compound 3) is an **EGFR tyrosine kinase inhibitor with an IC₅₀** of 2.7 μM .

HY-120857

BPIQ-II hydrochloride PD 158294	Others	Others
BPIQ-II is a linear imidazoloquinazoline that potently inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR; IC₅₀=8 pM). It is selective for EGFR over an assortment of other tyrosine and serine/threonine kinases. Cellular studies indicate that BPIQ-II can enter cells and very selectively shut down EGF-stimulated signal transmission by binding competitively at the ATP site of EGFR.

HY-156912

Tyrosine kinase-IN-7	EGFR	Cancer
Tyrosine kinase-IN-7 (compound 13h) is an inhibitor of the tyrosine kinase EGFR. The IC₅₀s for inhibiting EGFR(WT) and EGFR(T790M) are 0.630 μM and 0.956 μM respectively. Tyrosine kinase-IN-7 has antitumor activity against four cancer cell lines (HepG2, HCT-116, MCF-7, and A431) with IC₅₀s of 13.02 μM, 10.14 μM, 12.68 μM, and 47.05 μM, respectively .

HY-19730A

Olmutinib hydrochloride HM61713 hydrochloride; BI 1482694 hydrochloride	EGFR	Cancer
Olmutinib hydrochloride is an orally active and irreversible third **EGFR tyrosine kinase** inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib hydrochloride is used for NSCLC .

HY-101820

Simotinib	EGFR	Cancer
Simotinib is a selective, specific, and orally bioavailable *EGFR* tyrosine kinase inhibitor, with an IC₅₀ of 19.9 nM. Antineoplastic activities .

HY-101820A

Simotinib hydrochloride	EGFR	Cancer
Simotinib hydrochloride is a selective, specific, and orally bioavailable *EGFR* tyrosine kinase inhibitor, with an IC₅₀ of 19.9 nM. Antineoplastic activities .

HY-12000

AG490 120+ Cited Publications Tyrphostin AG490; Tyrphostin B42	EGFR STAT JAK Autophagy	Cancer
AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits *EGFR, Stat-3* and JAK2/3.

HY-153110A

Larotinib mesylate hydrate	EGFR IRAK Btk	Cancer
Larotinib mesylate hydrate is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with *EGFR* as the main target with an IC₅₀ of 0.6 nM .

HY-153110

Larotinib	EGFR IRAK Btk	Cancer
Larotinib is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with *EGFR* as the main target with an IC₅₀ of 0.6 nM .

HY-50898

Lapatinib 65+ Cited Publications GW572016; GW2016	EGFR Autophagy Ferroptosis	Cancer
Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and *EGFR* tyrosine kinase domains with IC₅₀ values against purified *EGFR* and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-147303

Sacibertinib	Trk Receptor EGFR	Cancer
Sacibertinib is a tyrosine kinase (Trk) inhibitor with EC₅₀ value of 110 nM and 244 nM for *EGFR-TK* phosphorylation and HER2, respectively. Antineoplastic activity .

HY-136430

JCN037 JGK037	EGFR	Cancer
JCN037 (JGK037) is non-covalent and BBB-penetrant *EGFR* tyrosine kinase inhibitor, with IC₅₀ values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRvⅢ, respectively .

HY-145844

EGFR-IN-44	EGFR Apoptosis	Cancer
EGFR-IN-44 (Compound 6a) is a potent, orally active *EGFR* tyrosine kinase inhibitor with an IC₅₀ of 4.11 nM. EGFR-IN-44 induces cell apoptosis and shows an oral bioavailability value of 33.57%. EGFR-IN-44 can be studied for non-small-cell lung cancers .

HY-19730

Olmutinib 5+ Cited Publications HM61713; BI 1482694	EGFR	Cancer
Olmutinib (HM61713; BI-1482694) is an orally active and irreversible third **EGFR tyrosine kinase** inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib is used for NSCLC .

HY-50898A

Lapatinib ditosylate 65+ Cited Publications GW572016 ditosylate; GW2016 ditosylate	EGFR Autophagy Ferroptosis	Cancer
Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the ErbB-2 and *EGFR* tyrosine kinase domains with IC₅₀ values against purified *EGFR* and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898B

Lapatinib ditosylate monohydrate 65+ Cited Publications GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate	EGFR Autophagy Ferroptosis	Cancer
Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and *EGFR* tyrosine kinase domains with IC₅₀ values against purified *EGFR* and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-137433

Befotertinib 1 Publications Verification D-0316	EGFR	Cancer
Befotertinib (D-0316) is the third-generation **EGFR tyrosine kinase** inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC) .

HY-50898C

Lapatinib tosylate GW572016 tosylate; GW2016 tosylate	EGFR Ferroptosis Autophagy	Cancer
Lapatinib (GW572016) tosylate is a potent, orally active inhibitor of the ErbB-2 and *EGFR* tyrosine kinase domains with IC₅₀ values against purified *EGFR* and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-112405

BPIQ-I PD 159121	EGFR	Cancer
BPIQ-I (PD 159121) is a potent and ATP-competitive **EGFR tyrosine kinase** inhibitor.. BPIQ-I shows anti-proliferative actively .

HY-156741

EGFR-IN-87	EGFR	Cancer
EGFR-IN-87 is a *EGFR* tyrosine kinase inhibitor. EGFR-IN-87 has IC₅₀ value of 3.1 nM, 1.3 nM and 7.1 nM for EGFR_d746-750, EGFR_L858R/T790 and EGFR_WT in A431 cells, respectively. EGFR-IN-87 can be used for cancer diseases research .

HY-129510

4-Methyl erlotinib	EGFR	Cancer
4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .

HY-100636

Gefitinib N-oxide	EGFR	Cancer
Gefitinib N-oxide is the N-oxide derivative of Gefitinib. Gefitinib is an **EGFR tyrosine kinase inhibitor, with IC₅₀** of 2-37 nM in NR6wtEGFR cells .

HY-12806

AG1557	EGFR	Cancer
AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has a pIC₅₀ value of 8.194 .

HY-100636A

Gefitinib N-oxide hydrochloride	EGFR	Cancer
Gefitinib N-oxide hydrochloride is the N-oxide derivative of Gefitinib. Gefitinib is an **EGFR tyrosine kinase inhibitor, with IC₅₀** of 2-37 nM in NR6wtEGFR cells .

HY-137433A

Befotertinib mesylate D-0316 mesylate	EGFR	Cancer
Befotertinib (D-0316) mesylate is the third-generation **EGFR tyrosine kinase** inhibitor. Befotertinib (D-0316) mesylate can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC) .

HY-130616

EGFR-IN-11	EGFR Apoptosis	Cancer
EGFR-IN-11 is a fourth-generation *EGFR*-tyrosine kinase inhibitor (EGFR-TKI) with an IC₅₀ of 18 nM for triple mutant EGFR ^{L858R/T790M/C797S}. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1 .

HY-142680

EGFR-IN-23	EGFR	Cancer
EGFR-IN-23 is a potent *EGFR* TKI (tyrosine kinase inhibitor) with an IC₅₀ of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8) .

HY-164413

CLM3	VEGFR EGFR RET Apoptosis	Cancer
CLM3, a pyrazolopyrimidine derivative, is a multiple *tyrosine* kinase inhibitor. CLM3 shows antiproliferative and proapoptotic activity on endothelial and cancer cells, synergistically enhanced by SN38 (HY-13704). These effects are mainly due to its inhibition of phosphorylation of VEGFR-2, *EGFR* and RET tyrosine kinases and their related signaling pathways .

HY-50895S

Gefitinib-d8 ZD1839-d₈	EGFR Autophagy	Cancer
Gefitinib-d₈ is a deuterium labeled Gefitinib. Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells[1][2].

HY-161866

EGFR-IN-118	EGFR	Cancer
EGFR-IN-118 (Compound 4a) is an inhibitor for the tyrosine kinase *EGFR. EGFR-IN-118 demonstrates anti-cancer property, inhibiting the proliferation of MCF-7 and PC3 with IC₅₀* of 2.53 and 3.25 µg/ml. EGFR-IN-118 exhibits antioxidant efficacy, inhibiting the DPPH free radicals with IC₅₀ of 10.04 µg/ml .

HY-101084

NSC 228155 5+ Cited Publications	EGFR Histone Acetyltransferase Epigenetic Reader Domain	Cancer
NSC 228155 is an activator of *EGFR, binds to the extracellular region of EGFR* and enhance tyrosine phosphorylation of EGFR . NSC 228155 is also a potent inhibitor of KIX-KID interaction, inhibits kinase-inducible domain (KID) from CREB and KID-interacting domain (KIX) from CBP, with an IC₅₀ of 0.36 μM .

HY-153268

BDTX-1535 EGFR-IN-76	EGFR	Cancer
BDTX-1535 (EGFR-IN-76, compound 37A) is an orally active, brain-penetrant, selective and potent *EGFR* tyrosine kinase inhibitor. BDTX-1535 achieves potent anti-tumor activity against EGFR alterations and amplification across models including NSCLC, GBM PDX and intracranial tumors .

HY-152098

HX103	EGFR	Cancer
HX103 is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-based fluorogenic probe. HX103 inhibits EGFR 19 del, EGFR L858R, EGFR wild type and EGFR T790M with IC₅₀s of 1.3, 1.5, 4.0 and 977 nM, respectively. HX103 can be used for quantifying active-EGFR to predict agent sensitivity in NSCLC patients with EGFR-activating mutations .

Cat. No.	Product Name

HY-L016

Protein Tyrosine Kinase Compound Library

1,140 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,140 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L075

Anti-Lung Cancer Compound Library

1,990 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 1,990 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-50895G

Gefitinib (GMP) ZD1839 (GMP)	Fluorescent Dye
Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active *EGFR* tyrosine kinase inhibitor .

Cat. No.	Product Name	Type

HY-50895G

Gefitinib (GMP) ZD1839 (GMP)	Biochemical Assay Reagents
Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active *EGFR* tyrosine kinase inhibitor .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18963

Lavendustin A RG-14355	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Disease Research Fields Cancer	EGFR
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀ of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-14596

Genistein Maximum Cited Publications 42 Publications Verification NPI 031L	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Microorganisms Leguminosae Glycine max (L.) merr Sunscreen Phenols Polyphenols Cosmetic Research Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones Cancer	EGFR Autophagy Apoptosis Endogenous Metabolite
Genistein, a soy isoflavone, is a multiple **tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis**, the cell cycle, and angiogenesis and inhibiting metastasis.

HY-131257

Gefitinib impurity 1	Classification of Application Fields Disease Research Fields Cancer	Drug Metabolite
Gefitinib impurity 1 is the impurity of Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active **EGFR tyrosine kinase inhibitor with an IC₅₀ of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC₅₀ of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy**. Gefitinib has antitumour activity .

HY-133779

Gefitinib impurity 5	Classification of Application Fields Disease Research Fields Cancer	Drug Metabolite
Gefitinib impurity 5 is the impurity of Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active **EGFR tyrosine kinase inhibitor with an IC₅₀ of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC₅₀ of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy**. Gefitinib has antitumour activity .

HY-100663

Gefitinib impurity 2	Classification of Application Fields Disease Research Fields Cancer	EGFR
Gefitinib impurity 2 is the impurity of Gefitinib. Gefitinib (ZD1839; HY-50895) is a potent, selective and orally active **EGFR tyrosine kinase inhibitor with an IC₅₀ of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC₅₀ of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy**. Gefitinib has antitumour activity .

HY-14596R

Genistein (Standard) Maximum Cited Publications 42 Publications Verification NPI 031L (Standard)	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Leguminosae Glycine max (L.) merr Sunscreen Phenols Cosmetic Research Glycyrrhiza uralensis Fisch. Disease Research Fields Cancer	EGFR Autophagy Apoptosis Endogenous Metabolite
Genistein (Standard) is the analytical standard of Genistein. This product is intended for research and analytical applications. Genistein, a soy isoflavone, is a multiple **tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis**, the cell cycle, and angiogenesis and inhibiting metastasis.

HY-N4201

β-Hydroxyisovalerylshikonin	Quinones Classification of Application Fields Source classification Phenols Polyphenols Plants Lithospermum erythrorhizon Sieb. et Zucc. Naphthalene Quinones Disease Research Fields Boraginaceae Cancer	EGFR Src
Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermum erythrorhizon, acts as a potent inhibitor of *protein tyrosine* kinases (PTK), with IC₅₀*s of 0.7μM and 1μM for EGFR* and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells .

HY-16558

Butein 4 Publications Verification 2’,3,4,4’-tetrahydroxy Chalcone	Structural Classification Chalcones Flavonoids other families Classification of Application Fields Anti-aging Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for *EGFR* and p60 ^c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-N12726

Halociline	Structural Classification Microorganisms Marine natural products Source classification Phenols Marine microorganism	p38 MAPK MMP
Halociline, a derivative of alkaloids, that can be isolated from the marine fungus Penicillium griseofulvum. Halociline targets MAPK1, MMP-9, and PIK3CA in gastric cancer cells, potentially mediated by diverse pathways including cancer, lipid metabolism, atherosclerosis, and EGFR tyrosine kinase inhibitor resistance. Halociline possesses antimicrobial, antioxidant and biofilm inhibitory activities .

HY-16558R

Butein (Standard)	Structural Classification Chalcones Flavonoids other families Source classification Phenols Polyphenols Plants	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein (Standard) is the analytical standard of Butein. This product is intended for research and analytical applications. Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

Species:	Human (3)
Tag:	His (2) Fc (1)
Source:	HEK293 (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P70189

	EGFR vIII Protein, Human (HEK293, His) rHuEpidermal Growth Factor Receptor/EGFR vIII, His; Epidermal growth factor receptor; EGFR; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; EGFR	Human	HEK293
	The EGFRvIII protein is a transmembrane glycoprotein in the protein kinase superfamily that acts as a receptor for epidermal growth factor. It acts on the cell surface, binds to epidermal growth factor, triggers receptor dimerization and tyrosine autophosphorylation, and promotes cell proliferation. EGFR vIII Protein, Human (HEK293, His) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with C-6*His labeled tag. The total length of EGFR vIII Protein, Human (HEK293, His) is 354 a.a., with molecular weight of 61-75 kDa.

HY-P70608

	EGFR vIII Protein, Human (HEK293, Fc) 1 Publications Verification Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR vIII protein is a transmembrane glycoprotein in the protein kinase superfamily that acts as a receptor for epidermal growth factor. It acts on the cell surface, binds to epidermal growth factor, triggers receptor dimerization and tyrosine autophosphorylation, and promotes cell proliferation. EGFR vIII Protein, Human (HEK293, Fc) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P70613

	EGFR Protein, Human (621a.a, HEK293, His) Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-6*His labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, His) is 621 a.a., with molecular weight of 90-120 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-50895S

Gefitinib-d8
Gefitinib-d₈ is a deuterium labeled Gefitinib. Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells[1][2].

HY-50898S

Lapatinib-d4
Lapatinib-d₄ is the deuterium labeled Lapatinib (HY-50898). Lapatinib is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1][2].

HY-50896S

Erlotinib-d6
Erlotinib-d₆ (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR[1]. Erlotinib-d6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-50896S1

Erlotinib-13C6
Erlotinib- ¹³C₆ is a ¹³C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1].

HY-15772S3

Asandeutertinib
Asandeutertinib (Osimertinib-d3; AZD-9291-d3) is a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with antineoplastic effect .

HY-50898S1

Lapatinib-d7 dihydrochloride
Lapatinib-d₇ (dihydrochloride) is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

HY-50898S2

Lapatinib-d5
Lapatinib-d₅ is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

HY-50898S3

Lapatinib-d4-1
Lapatinib-d₄-1 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

HY-10260S1

Vandetanib-d4
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].

HY-10260S

Vandetanib-d6
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].

HY-10260S2

Vandetanib-13C6
Vandetanib-13C6 is a deuterated labeled Vandetanib . Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-32721S

Neratinib-d6
Neratinib-d₆ (HKI-272-d6) is the deuterium labeled Neratinib. Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50s of 59 nM and 92 nM for HER2 and EGFR, respectively.

HY-50895S1

Gefitinib-d6
Gefitinib-d₆ is the deuterium labeled Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity[1][2].

HY-14596S

Genistein-d4
Genistein-d₄ is the deuterium labeled Genistein. Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis[1][2].

HY-50895S2

Gefitinib-d3

Gefitinib-d₃ (ZD1839-d3) is the deuterium labeled Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity[1][2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80648

	EGFR Antibody (YA775) EGFR; ERBB; ERBB1; HER1; Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1	WB, ICC/IF, IP	Human, Monkey
	EGFR Antibody (YA775) is a non-conjugated and Mouse origined monoclonal antibody about 134 kDa, targeting to EGFR (6H11). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Monkey.

HY-P80808

	Phospho-EGFR (Tyr1068) Antibody EGFR; ERBB; ERBB1; HER1; Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1	WB, IHC-F, IHC-P, ICC/IF	Human
	Phospho-EGFR (Tyr1068) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR (Tyr1068). It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human.

HY-P80809

	Phospho-EGFR (Tyr1092) Antibody EGFR; ERBB; ERBB1; HER1; Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1	WB, IHC-P	Human, Mouse, Rat
	Phospho-EGFR (Tyr1092) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR (Tyr1092). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

HY-P80810

	Phospho-EGFR (Tyr1173) Antibody EGFR; ERBB; ERBB1; HER1; Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	Phospho-EGFR (Tyr1173) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR (Tyr1173). It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-50896

Erlotinib 85+ Cited Publications CP-358774; NSC 718781; OSI-774		Alkynes
Erlotinib (CP-358774) is a directly acting *EGFR* tyrosine kinase inhibitor, with an IC₅₀ of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC₅₀ of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-139300A

Epitinib succinate HMPL-813 succinate		Alkynes
Epitinib succinate is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer . Epitinib (succinate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-50896S

Erlotinib-d6 CP-358774-d₆; NSC 718781-d₆; OSI-774-d₆		Alkynes
Erlotinib-d₆ (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR[1]. Erlotinib-d6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-50896S1

Erlotinib-13C6 CP-358774-¹³C₆; NSC 718781-¹³C₆; OSI-774-¹³C₆		Alkynes
Erlotinib- ¹³C₆ is a ¹³C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1].

HY-129510

4-Methyl erlotinib		Alkynes
4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .

HY-139300

Epitinib HMPL-813		Alkynes
Epitinib is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib can be used for the research of cancer . Epitinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-131088

N3-PEG8-Phe-Lys-PABC-Gefitinib		Azide
N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

EGFR tyrosine kinase

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Natural
Products